These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 32150611)

  • 1. Single-cell mutational profiling enhances the clinical evaluation of AML MRD.
    Ediriwickrema A; Aleshin A; Reiter JG; Corces MR; Köhnke T; Stafford M; Liedtke M; Medeiros BC; Majeti R
    Blood Adv; 2020 Mar; 4(5):943-952. PubMed ID: 32150611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal/Measurable Residual Disease Monitoring in
    Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.
    Rothenberg-Thurley M; Amler S; Goerlich D; Köhnke T; Konstandin NP; Schneider S; Sauerland MC; Herold T; Hubmann M; Ksienzyk B; Zellmeier E; Bohlander SK; Subklewe M; Faldum A; Hiddemann W; Braess J; Spiekermann K; Metzeler KH
    Leukemia; 2018 Jul; 32(7):1598-1608. PubMed ID: 29472724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Next-generation Sequencing-based Gene Panel Test to Detect Measurable Residual Disease in Acute Myeloid Leukemia.
    Kim JJ; Jang JE; Lee HA; Park MR; Kook HW; Lee ST; Choi JR; Min YH; Shin S; Cheong JW
    Ann Lab Med; 2023 Jul; 43(4):328-336. PubMed ID: 36843401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
    Jongen-Lavrencic M; Grob T; Hanekamp D; Kavelaars FG; Al Hinai A; Zeilemaker A; Erpelinck-Verschueren CAJ; Gradowska PL; Meijer R; Cloos J; Biemond BJ; Graux C; van Marwijk Kooy M; Manz MG; Pabst T; Passweg JR; Havelange V; Ossenkoppele GJ; Sanders MA; Schuurhuis GJ; Löwenberg B; Valk PJM
    N Engl J Med; 2018 Mar; 378(13):1189-1199. PubMed ID: 29601269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse.
    Onecha E; Rapado I; Luz Morales M; Carreño-Tarragona G; Martinez-Sanchez P; Gutierrez X; Sáchez Pina JM; Linares M; Gallardo M; Martinez-López J; Ayala R
    Haematologica; 2021 Sep; 106(9):2325-2333. PubMed ID: 32732356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Höllein A; Meggendorfer M; Dicker F; Jeromin S; Nadarajah N; Kern W; Haferlach C; Haferlach T
    Blood Adv; 2018 Nov; 2(22):3118-3125. PubMed ID: 30455361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical significance of MRD in AML].
    Ishikawa Y
    Rinsho Ketsueki; 2020; 61(9):1150-1159. PubMed ID: 33162510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse.
    Press RD; Eickelberg G; Froman A; Yang F; Stentz A; Flatley EM; Fan G; Lim JY; Meyers G; Maziarz RT; Cook RJ
    Am J Hematol; 2019 Aug; 94(8):902-912. PubMed ID: 31124175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia.
    Hasserjian RP; Steensma DP; Graubert TA; Ebert BL
    Blood; 2020 May; 135(20):1729-1738. PubMed ID: 32232484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing.
    Ahn JS; Kim T; Jung SH; Ahn SY; Jung SY; Song GY; Kim M; Yang DH; Lee JJ; Choi S; Lee JY; Park SK; Moon JH; Lee HY; Kim KH; Cai Y; Yi SY; Novitzky-Basso I; Zhang Z; Kim HJ; Kim DDH
    Bone Marrow Transplant; 2021 May; 56(5):1159-1170. PubMed ID: 33279940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should minimal residual disease guide therapy in AML?
    Paietta E
    Best Pract Res Clin Haematol; 2015; 28(2-3):98-105. PubMed ID: 26590765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing.
    Balagopal V; Hantel A; Kadri S; Steinhardt G; Zhen CJ; Kang W; Wanjari P; Ritterhouse LL; Stock W; Segal JP
    PLoS One; 2019; 14(10):e0224097. PubMed ID: 31658273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy.
    Uy GL; Duncavage EJ; Chang GS; Jacoby MA; Miller CA; Shao J; Heath S; Elliott K; Reineck T; Fulton RS; Fronick CC; O'Laughlin M; Ganel L; Abboud CN; Cashen AF; DiPersio JF; Wilson RK; Link DC; Welch JS; Ley TJ; Graubert TA; Westervelt P; Walter MJ
    Leukemia; 2017 Apr; 31(4):872-881. PubMed ID: 27740633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML.
    Tsai CH; Tang JL; Tien FM; Kuo YY; Wu DC; Lin CC; Tseng MH; Peng YL; Hou MF; Chuang YK; Liu MC; Liu CW; Yao M; Lin LI; Chou WC; Chen CY; Hou HA; Tien HF
    Blood Adv; 2021 May; 5(10):2456-2466. PubMed ID: 33999144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonal evolution of acute myeloid leukemia from diagnosis to relapse.
    Vosberg S; Greif PA
    Genes Chromosomes Cancer; 2019 Dec; 58(12):839-849. PubMed ID: 31478278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia.
    Vonk CM; Al Hinai ASA; Hanekamp D; Valk PJM
    Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
    Thol F; Gabdoulline R; Liebich A; Klement P; Schiller J; Kandziora C; Hambach L; Stadler M; Koenecke C; Flintrop M; Pankratz M; Wichmann M; Neziri B; Büttner K; Heida B; Klesse S; Chaturvedi A; Kloos A; Göhring G; Schlegelberger B; Gaidzik VI; Bullinger L; Fiedler W; Heim A; Hamwi I; Eder M; Krauter J; Schlenk RF; Paschka P; Döhner K; Döhner H; Ganser A; Heuser M
    Blood; 2018 Oct; 132(16):1703-1713. PubMed ID: 30190321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia.
    Hirsch P; Tang R; Abermil N; Flandrin P; Moatti H; Favale F; Suner L; Lorre F; Marzac C; Fava F; Mamez AC; Lapusan S; Isnard F; Mohty M; Legrand O; Douay L; Bilhou-Nabera C; Delhommeau F
    Haematologica; 2017 Jul; 102(7):1227-1237. PubMed ID: 28302711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.